CELLPLY SRL

Their core work

CELLPLY is a Bologna-based medtech SME specializing in microfluidic lab-on-chip devices for oncology diagnostics and personalized cancer treatment. Their core product concept — ONCOSMART — profiles individual cancer patients' ex-vivo cell responses to chemotherapy drugs, enabling clinicians to select the most effective treatment before administration. They develop bedside diagnostic devices that test patient tumor cells against candidate therapies in real time, bridging the gap between laboratory research and point-of-care clinical decision-making. Their work targets leukemia and solid cancer patients undergoing chemotherapy, with the goal of reducing trial-and-error prescribing.

What they specialise in

How they've shifted over time

In their early phase (2016–2017), CELLPLY's language was dominated by device and platform terms: microfluidics, lab-on-chip, point-of-care, diagnostics — indicating the focus was on building and validating the technology itself. By 2018–2021, the vocabulary shifted toward biological and clinical outcomes: ex-vivo cell response, clinical trials, cancer treatment, personalised medicine — showing the device had matured enough that the emphasis moved to proving clinical utility. This is a classic medtech progression: from "does the device work?" to "does the device improve patient outcomes?"

CELLPLY is on a trajectory from device-maker to clinical solution provider — future collaborations are likely to involve hospital networks, oncology clinics, and regulatory validation partners rather than pure technology developers.

How they like to work

CELLPLY operated exclusively as a coordinator across both H2020 projects and received all funding without any consortium partners, which is characteristic of the EU SME Instrument — a grant designed specifically for single innovative companies. This means their EU track record reflects internal R&D capability rather than consortium-building experience. Anyone looking to partner with them would be entering as a new collaborator into a company accustomed to driving its own agenda independently.

CELLPLY's H2020 activity shows zero recorded consortium partners and no cross-border collaborations, consistent with the solo-applicant model of the SME Instrument. Their network for future Horizon Europe projects would need to be built from scratch if they pursue collaborative calls.

What sets them apart

CELLPLY occupies a specific and defensible niche: a device company that tests living tumor cells from individual patients against chemotherapy options before treatment begins — a "test before you treat" approach to oncology. Unlike general diagnostics companies, their focus is tightly scoped to cancer chemotherapy selection, which gives them deep domain credibility in a high-value clinical problem. For consortium builders working on personalized medicine, cancer diagnostics, or lab-on-chip medical devices, CELLPLY brings both the technology and the oncology-specific clinical context.

Highlights from their portfolio

• ONCOSMART
  The Phase 2 SME Instrument award of €2.34M (2018–2021) is a strong market validation signal — this highly competitive grant is awarded only to companies with credible commercialization potential, confirming the technology passed rigorous EU evaluation twice.
• Oncosmart
  The Phase 1 feasibility grant (2016) launched the ONCOSMART concept and established the core value proposition of bedside microfluidic profiling for leukemia and cancer patients.